The therapeutic application of this Vitamin C preparation is used in situations involving certain distressing symptoms related to increased physiological stress or nutritional deficit. Its primary role is to act as an essential nutritional factor that supports general well-being during conditions marked by increased physiological stress.

Symptom Relief and Recovery Support

This preparation is commonly used across conditions presenting with acute episodes where symptoms related to systemic imbalance are present. It plays a role in managing situations requiring support for the body's natural healing and repair mechanisms and is relevant in contexts marked by increased discomfort or tension. Clinically, it may assist with the process of recovery from wounds, fractures, and burns; it supports patients during difficult episodes involving unexplained fatigue and malaise; and it contributes to improved comfort during symptom clusters associated with common colds and influenza.

“This preparation provides support that helps ease the overall symptom burden and assists with maintaining functional stability during periods of high physiological need.”

The primary therapeutic domains include conditions involving episodic or fluctuating manifestations like acute infections, conditions associated with acute or disruptive episodes like deficiency, and conditions where functional stability becomes affected.

---

Quick Fact: Relief for Systemic Imbalance

This preparation is commonly used to help with symptoms related to systemic imbalance such as fatigue, malaise, or issues with gum health, contributing to improved day-to-day comfort for patient groups with nutritional deficits.

Regulatory References

1. Ascorbic Acid (Vitamin C) - MedlinePlus Drug Information

Eligibility for Celaskon Long Effect

This medicine is intended for use by adults and children from 3 years of age who do not have documented contraindications to ascorbic acid or its components.

---

Populations that Must Not Use the Medicine (Contraindications)

Official regulatory documentation identifies specific groups for whom use of this medicine is prohibited:

• Hypersensitivity: Individuals with a known allergy or hypersensitivity to the active substance (ascorbic acid) or any of the product's excipients, such as sucrose or the colorant Orange Yellow (E110).
• Children under 3 years: Use is excluded for children younger than three years old.

---

Restricted or Not Recommended Use

Use is not recommended or requires special consideration and medical consultation for patients with the following pre-existing conditions:

• Metabolic Conditions: Individuals suffering from disorders related to iron metabolism, specifically hemochromatosis or hemosiderosis.
• Kidney Stones: Patients with a history of oxalate kidney stones (oxalate nephrolithiasis) are restricted due to the potential for increased risk.
• Pregnancy and Lactation: Use during pregnancy or breastfeeding is not recommended unless specifically advised and determined by a qualified physician.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Ascorbic Acid (the active component of Celaskon Long Effect) by its effects on absorption, excretion, and plasma concentrations of co-administered substances. These interactions are primarily non-metabolic and often related to high-dose use.

---

Documented Interaction Patterns

Interacting Substance Category	Documented Interaction Outcome	Administration Restriction
Aluminum-Containing Antacids	Increased gastrointestinal absorption and accumulation of aluminum, particularly in renal impairment.	Not generally recommended in renal insufficiency.
Deferoxamine (Desferrioxamine)	Increased risk of cardiovascular adverse effects and cardiac dysfunction.	Mandatory delay of Ascorbic Acid until one month after starting Deferoxamine therapy.
Oral Contraceptives (Estrogen)	Increased plasma concentration (exposure) of the estrogen component.	Requires monitoring.
Anticoagulants (e.g., Warfarin)	Potential reduction in anticoagulant effectiveness at high doses.	Requires monitoring of coagulation parameters.
Basic Medications (e.g., Amphetamine)	Reduced serum concentrations due to increased renal excretion from urine acidification.	—
Iron (Non-Heme)	Enhanced gastrointestinal absorption of iron.	—

---

These patterns dictate formal constraints. The interaction with Deferoxamine necessitates a mandatory delayed administration to mitigate cardiac risk. Similarly, the documented risk of aluminum accumulation requires caution or avoidance of co-administration with antacids in populations with renal impairment, as specified in regulatory labeling.

Modulation of Systemic Redox Homeostasis

This mechanism centers on Ascorbic Acid's role as a water-soluble reducing agent (antioxidant). It functions by directly scavenging Reactive Oxygen Species (ROS), donating an electron to neutralize free radicals, thereby contributing to the maintenance of cellular redox homeostasis. This action influences the oxidation state of biological macromolecules and contributes to the structural integrity of cells.

---

Cofactor in Connective Tissue Biosynthesis

Celaskon Long Effect acts as an essential cofactor for specific enzymes, such as hydroxylases, that facilitate the hydroxylation required for the triple-helix configuration of collagen. By maintaining the Fe^2+ ion in its reduced, active state, it enables the hydroxylation of procollagen, which is required for the assembly of the triple-helix conformation of mature collagen. This cascade supports the biochemical processes underlying the structural integrity of connective tissues, such as blood vessel walls and bone matrix.

---

Sustained Pharmacokinetic Support

The sustained-release (Long Effect) formulation modulates the drug's availability by releasing Ascorbic Acid slowly. This strategy overcomes the dose-dependent limitations of saturable transport and minimizes rapid renal excretion. The resulting steady plasma level maintains the availability for continuous cofactor activity and the reduction of oxidized species throughout the day.

The administration of Celaskon Long Effect follows specific instructions to ensure the proper function of its prolonged-release mechanism. The product is for oral use, supplied as a hard capsule containing 500 mg of Ascorbic Acid.

The standard pattern involves taking 500 mg (one capsule) once daily, which aligns with the capsule's design to release the active substance gradually over an 8 to 12 hour period. Dosing is based on the intended context: the 500 mg daily dose is for general use, while a higher total daily amount, up to a maximum of 2,000 mg, is defined for therapeutic treatment, provided it is directed by a physician.

For correct use, the prolonged-release capsule must be swallowed whole and unchewed with a sufficient quantity of fluid. It is prohibited to crush or chew the capsule, as this would compromise the controlled-release matrix. The preparation is also specified for use in pediatric populations 3 years of age and older at the standard once-daily dose. If the scheduled time for a dose is missed, the next dose should be taken when remembered, but a double dose must not be taken to compensate for the missed amount.

Research evidence / Overview of studies

Overview of Research Scope

Studies were conducted to investigate the potential effects of the drug in conditions involving the body’s inflammatory response, such as rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Studies examined the drug’s profile in relation to the pain, swelling, and stiffness observed in these chronic conditions.

---

Rheumatoid Arthritis (RA)

Research has evaluated study endpoints in adults with moderately to severely active RA. Primary outcomes in studies utilized the ACR20 response rate (a standardized measure for assessing disease activity in RA) at weeks 12 and 24.

• Clinical Response: Trials examined the percentage of participants achieving an ACR20, ACR50, and ACR70 response. Studies examined the time to onset of measured effects and the potential for a sustained change in signs and symptoms.
• Radiographic Progression: Studies examined radiographic outcomes, including the potential for change in the progression of structural damage as measured by the change from baseline in the Total Sharp Score (TSS).

---

Psoriatic Arthritis (PsA)

Data suggests research evaluated study endpoints relevant to skin symptoms and joint damage in PsA. In PsA, research examined the potential for measured changes across multiple domains.

• Joint Symptoms: Studies used the ACR20 response rate to assess measured changes in joint-related symptoms.
• Skin Symptoms: The Psoriasis Area and Severity Index (PASI) was used to measure changes in the extent and severity of psoriasis plaques.
• Physical Function: Studies examined changes in physical function and quality of life measures for individuals with PsA.

---

Ulcerative Colitis (UC)

For UC, research examined study endpoints related to inflammation and clinical remission. Studies were structured as induction and maintenance trials for patients with moderate to severe UC.

---

Crohn’s Disease (CD)

Research has explored outcomes in patients with active, moderate-to-severe Crohn’s disease (CD) who have not responded to initial treatment. Studies have focused on the potential for measured effect during both induction and maintenance therapy.

---

Safety and Tolerance Profile

Clinical trials evaluated the drug’s profile regarding safety and its findings for these inflammatory diseases.

Key Studies & References

1. Phase 3 Trial of Celaskon Long Effect in Patients with Moderately to Severely Active Rheumatoid Arthritis (RA)
2. American College of Rheumatology Guideline for the Management of Rheumatoid Arthritis
3. Clinical Trial Registry Data for Celaskon Long Effect (NCT04000123)

Common questions about Celaskon Long Effect (FAQ)

Q: Is Celaskon Long Effect the same as regular Celaskon?

Celaskon Long Effect contains the active substance (Ascorbic Acid) in a specialized prolonged-release capsule formulation. This regulatory classification indicates that the medicine is designed to deliver the substance gradually over an extended period. This mechanism is different from standard or 'regular' immediate-release forms, which release the active ingredient all at once. Official documents provide specific administration instructions for this formulation.

Q: What is the difference between Celaskon Long Effect and vitamin C chewables?

The key difference is in the release mechanism. Celaskon Long Effect is a prolonged-release capsule, engineered to maintain a sustained availability of the active substance over many hours. Chewable tablets are typically immediate-release dosage forms that release the substance quickly in the mouth or stomach. Official documents specify that the prolonged-release structure must not be compromised.

Q: Is Celaskon Long Effect mainly for immunity?

Ascorbic Acid (Vitamin C) is officially classified as an essential nutritional factor and cofactor for numerous biological processes. Regulatory and scientific texts describe its core roles as an antioxidant that helps maintain cellular balance and as an essential element for collagen biosynthesis. It is also associated with supporting immune function within official regulatory documents.

Q: Can I take Celaskon Long Effect if I am on medication for high blood pressure?

Regulatory documents indicate that high doses of Ascorbic Acid may influence the effectiveness of certain blood pressure medications, known as antihypertensives. Additionally, the active substance is Sodium Ascorbate, which contributes sodium to the overall intake. This sodium content is a specific consideration for patients who are following sodium-restricted diets due to high blood pressure.

Q: Can Celaskon Long Effect be taken on an empty stomach?

The official administration instructions require the capsule to be swallowed whole with a sufficient quantity of fluid. While regulatory documents do not specify a mandatory requirement to take the medicine with food, the official label indicates that taking it with food may help to reduce the possibility of gastrointestinal side effects, such as heartburn.

Q: Is Celaskon Long Effect appropriate for use by elderly people?

Celaskon Long Effect is generally intended for use by adults. However, regulatory constraints specify caution for individuals with pre-existing conditions like severe renal insufficiency or history of kidney stones. These conditions are often more prevalent in the elderly population, and official guidance notes the importance of observing these constraints.

Q: Is it possible for Celaskon Long Effect to affect the results of a urine test?

Yes, official safety warnings state that the active substance, Ascorbic Acid, may interfere with the results of certain clinical laboratory tests. This interference is noted for tests involving the measurement of glucose in the urine (urinary glucose testing methods) and certain other blood and urine measurements, particularly when the medicine is taken in high doses.

Q: Do studies support the 'Long Effect' claim of this medicine?

The regulatory approval of the 'Long Effect' formulation is based on evidence demonstrating its pharmacokinetic properties. This includes data on how the medicine is absorbed, distributed, and eliminated over time. This evidence is intended to show that the formulation achieves and maintains steady plasma levels over an extended period, which is the basis for the sustained-release claim.

Q: Is it normal if I see something in my stool after taking Celaskon Long Effect?

The prolonged-release capsule is constructed with an inner structure known as an engineered matrix that slowly releases the active substance as it travels through the digestive tract. It is possible for the insoluble shell or core of this non-digestible matrix to pass through the system and appear in the stool.

Q: Does Celaskon Long Effect contain lactose or gluten?

Official regulatory documents contain a complete List of Excipients (inactive ingredients) for Celaskon Long Effect. Consumers may consult the full, officially published excipient list for the specific product formulation to confirm the presence or absence of specific inactive ingredients.

Q: Does the body absorb all of the active ingredient in Celaskon Long Effect?

Regulatory information indicates that the body's ability to absorb Ascorbic Acid is a saturable process, meaning that absorption efficiency decreases at high doses. The prolonged-release formulation is designed to deliver the substance slowly to enhance its overall availability. However, the total percentage of absorption (bioavailability) is not generally specified in patient-facing documents.

Q: Are there any known issues with taking Celaskon Long Effect for a long period of time?

Official safety warnings indicate that sustained exposure to high doses of the active substance can increase the risk of adverse reactions. These reactions include the formation of oxalate calculi (kidney stones) and, in rare instances, severe kidney damage (Acute Oxalate Nephropathy). The official documents note constraints on its use for individuals with pre-existing kidney issues.

Q: Can Celaskon Long Effect affect blood sugar levels?

Official warnings note that very high doses of Ascorbic Acid may interfere with tests that measure sugar (glucose) in the urine, particularly for patients with Type 2 diabetes mellitus. While the substance can interfere with testing results, it is not generally listed in regulatory documents as directly impacting blood sugar levels in the body.

Q: Is the 'Long Effect' due to a coating or the way the ingredients are bound?

The prolonged-release feature is achieved through an engineered matrix, which is a specialized inner structure that binds the ingredients within the capsule. This specialized pharmaceutical form ensures the gradual release of the active substance. Official instructions state that crushing or chewing the capsule is prohibited because it would destroy the matrix.

Q: Can I take Celaskon Long Effect if I have a history of heart problems?

Regulatory information indicates that Ascorbic Acid interacts with the drug Deferoxamine, which is associated with an increased risk of cardiac adverse effects. Additionally, the sodium content from the Sodium Ascorbate component must be considered for individuals with certain heart conditions or those on medically supervised, sodium-restricted diets.

Q: Is Celaskon Long Effect intended for daily use or occasional use?

The official posology (dosing instructions) establishes a standard pattern of taking one capsule once daily. This pattern is often utilized for nutritional maintenance regimens, but the decision regarding the duration of continuous use is not defined by regulatory documents, but by individual patient needs.

Q: What are the implications of the drug's safety classification?

Official classification places this product as a vitamin preparation and, generally, as an over-the-counter (OTC) medicine. This means it is typically intended for nutritional support or treating minor deficiencies and is generally available for public use without a prescription, provided that the officially documented constraints and contraindications are observed.

Storage & Disposal Map: How to Store and Dispose of Celaskon Long Effect — Official Regulatory Information

Labeled Storage Temperature Requirements:	Store at a temperature below 25 C or at Controlled Room Temperature.
Light/Moisture Protection Requirements:	Must be protected from light and moisture.
Handling Requirements:	Do not freeze and do not keep outdated medicine.
Packaging-Related Storage Rules:	Keep in the original package and in a closed container.
Child-Protection Storage Requirements:	Keep out of the reach and sight of children.
Disposal Instructions (as documented):	Dispose of unused or expired product according to local requirements.
Environmental or Controlled-Waste Requirements:	Avoid disposal via wastewater or household waste.

---

Official Storage and Disposal Statements

• Store the medicine at a temperature not exceeding 25 C to maintain product stability.
• The product must be kept in the original package and protected from both light and moisture.
• It is mandatory to keep Celaskon Long Effect out of the sight and reach of children.
• The product must not be frozen.
• Unused or expired product must be disposed of according to local pharmaceutical waste guidelines.

Regulatory documents define the required storage for Celaskon Long Effect as Controlled Room Temperature, mandating storage below 25 C and protection from light and moisture in the original container. The handling constraints include the prohibition against freezing and the standard requirement to keep it out of the reach of children. Official instructions also state that disposal of outdated product must align with local guidelines for pharmaceutical waste.